Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Tunc, LutfiSubject: search.filters.subject.holmium

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Comparison of outcomes of Holmium enucleation of the prostate for small- and moderate-sized prostates
    (WILEY, 2021-01-01) Yilmaz, Sercan; Yalcin, Serdar; Yilmaz, Mehmet; Acikgoz, Onur; Aybal, Halil cagri; Gazel, Eymen; Kaya, Engin; Tunc, Lutfi
    There is an ongoing discussion in the literature on the surgical treatment option for small prostate size benign prostate hyperplasia (BPH) patients. This study aimed to evaluate the efficacy of Holmium laser enucleation of the prostate (HoLEP) surgery in small (<30 ml) and moderate (30-80 ml) prostate size as accepted in European Association of Urology guideline. We retrospectively analysed our database between May 2016 and May 2019 and patients who underwent HoLEP surgery. Patients who have prostate size <80 ml were included the study. These patients were divided into two group: group 1 with prostate size <30 ml (n: 64) and group 2 with prostate size 30-80 ml (n: 101). Enucleation time (ET), morcellation time (MT), total operation time (OT), enucleation efficiency (EE), morcellation efficiency (ME), intra- and post-operative complications were analysed. While EE and Hb drop were better in favour of group 2
  • Thumbnail Image
    Item
    Impact of metabolic syndrome on pre- and postoperative parameters in patients undergoing a HoLEP surgery
    (AVES, 2019-01-01) Aydogan, Tahsin Batuhan; Kaya, Engin; Gazel, Eymen; Yalcin, Serdar; Aybal, Halil Cagri; Tunc, Lutfi
    Objective: We aimed to investigate the safety and success of the holmium laser enucleation of prostate (HoLEP) surgery in patients with metabolic syndrome (MS) versus those without MS who have similar prostate sizes. Material and methods: Data from 120 patients who underwent HoLEP by a single surgeon between November 2015 and January 2018 were prospectively analyzed. Group 1 (n=40) and Group 2 (n=80) consisted of patients with and without MS, respectively. Preoperative-and postoperative third month control variables that were compared between the groups included hemoglobin (Hb) level